Directed evolution of a three-finger neurotoxin by using cDNA display yields antagonists as well as agonists of interleukin-6 receptor signaling

Molecular Brain

Volumn 4, Issue 1, 2011, Pages

  Naimuddin, Mohammed ^a,c   Kobayashi, Suzuko ^a   Tsutsui, Chihiro ^b   MacHida, Masayuki ^a   Nemoto, Naoto ^a,c   Sakai, Takafumi ^b   Kubo, Tai ^a,d  

^a NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^b SAITAMA UNIVERSITY   (Japan)

^c Saitama Industrial Technology Center   (Japan)

^d GIFU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CHOLINERGIC RECEPTOR; COMPLEMENTARY DNA; INTERLEUKIN 6 RECEPTOR; NEUROTOXIN; PROTEIN THREE FINGER NEUROTOXIN; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG; PEPTIDE; SNAKE VENOM;

ARTICLE; DIRECTED MOLECULAR EVOLUTION; IN VITRO STUDY; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; AMINO ACID SEQUENCE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG POTENTIATION; GENE EXPRESSION PROFILING; GENE LIBRARY; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; SEQUENCE ALIGNMENT;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; DIRECTED MOLECULAR EVOLUTION; GENE EXPRESSION PROFILING; GENE LIBRARY; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEUROTOXINS; PEPTIDES; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, INTERLEUKIN-6; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; SNAKE VENOMS;

EID: 78650952266     PISSN: None     EISSN: 17566606     Source Type: Journal    
DOI: 10.1186/1756-6606-4-2     Document Type: Article

References (58)

1. In vitro selection and evolution of proteins. A Pluckthun C Schaffitzel J Hanes L Jermutus, Adv Protein Chem 2000 55 367 403 11050939
2. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. GP Smith, Science 1985 228 1315 1317 10.1126/science.4001944 4001944
3. In-vitro protein evolution by ribosome display and mRNA display. D Lipovsek A Pluckthun, J Immunol Methods 2004 290 51 67 10.1016/j.jim.2004.04.008 15261571
4. In vitro virus: bonding of mRNA bearing puromycin at the 3'-terminal end to the C-terminal end of its encoded protein on the ribosome in vitro. N Nemoto E Miyamoto-Sato Y Husimi H Yanagawa, FEBS Lett 1997 414 405 408 10.1016/S0014-5793(97)01026-0 9315729
5. RNA-peptide fusions for the in vitro selection of peptides and proteins. RW Roberts JW Szostak, Proc Natl Acad Sci USA 1997 94 12297 12302 10.1073/pnas.94.23.12297 9356443
6. cDNA display: a novel screening method for functional disulfide-rich peptides by solid-phase synthesis and stabilization of mRNA-protein fusions. J Yamaguchi M Naimuddin M Biyani T Sasaki M Machida T Kubo T Funatsu Y Husimi N Nemoto, Nucleic Acids Res 2009 37 16 108 10.1093/nar/gkp514 19528071
7. Engineered proteins as specific binding reagents. HK Binz A Pluckthun, Curr Opin Biotechnol 2005 16 459 469 10.1016/j.copbio.2005.06.005 16005204
8. Binding proteins from alternative scaffolds. PA Nygren A Skerra, J Immunol Methods 2004 290 3 28 10.1016/j.jim.2004.04.006 15261569
9. Engineering novel binding proteins from nonimmunoglobulin domains. HK Binz P Amstutz A Pluckthun, Nat Biotechnol 2005 23 1257 1268 10.1038/nbt1127 16211069
10. Current view on the structure-function relationship of postsynaptic neurotoxins from snake venoms. T Endo N Tamiya, Pharmacol Ther 1987 34 403 451 10.1016/0163-7258(87)90002-7 3324114
11. Snake venom -neurotoxin and other 'three-finger' proteins. V Tsetlin, Eur J Biochem 1999 264 281 286 10.1046/j.1432-1327.1999.00623.x 10491072
12. Lynx1, an endogenous toxin-like modulator of nicotinic acetylcholine receptors in the mammalian CNS. JM Miwa I Ibanez-Tallon GW Crabtree R Snchez A Sali LW Role N Heintz, Neuron 1999 23 105 114 10.1016/S0896-6273(00)80757-6 10402197
13. SLURP-2, a novel member of the human Ly-6 superfamily that is up-regulated in psoriasis vulgaris. H Tsuji K Okamoto Y Matsuzaka H Iizuka G Tamiya H Inoko, Genomics 2003 81 26 33 10.1016/S0888-7543(02)00025-3 12573258
14. Molecular evolution and phylogeny of elapid snake venom three-finger toxins. BG Fry W Wüster RM Kini V Brusic A Khan D Venkataraman AP Rooney, J Mol Evol 2003 57 110 129 10.1007/s00239-003-2461-2 12962311
15. How do short neurotoxins bind to a muscular-type nicotinic acetylcholine receptor? F Teixeira-Clerc A Menez P Kessler, J Biol Chem 2002 277 25741 25747 10.1074/jbc.M200534200 12006581
16. Crystal structure of a Cbtx-AChBP complex reveals essential interactions between snake alpha-neurotoxins and nicotinic receptors. Y Bourne TT Talley SB Hansen P Taylor P Marchot, EMBO J 2005 24 1512 1522 10.1038/sj.emboj.7600620 15791209
17. Biological and clinical aspects of interleukin 6. T Hirano S Akira T Taga T Kishimoto, Immunol Today 1990 11 443 449 10.1016/0167-5699(90)90173-7 2127356
18. Interleukin 6 and autoimmune diseases. T Hirano T Kishimoto, Molecular Autoimmunity Academic Press, Talal N, 1991 177 194
19. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. PC Heinrich I Behrmann S Haan HM Hermanns G Müller-Newen F Schaper, Biochem J 2003 374 1 20 10.1042/BJ20030407 12773095
20. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. M Maes R Yirmyia J Noraberg S Brene J Hibbeln G Perini M Kubera P Bob B Lerer M Maj, Metab Brain Dis 2009 24 27 53 10.1007/s11011-008-9118-1 19085093
21. humans IL-6 is released from the brain during and after exercise and paralleled by enhanced IL-6 mRNA expression in the hippocampus of mice. P Rasmussen JC Vedel J Olesen H Adser MV Pedersen E Hart NH Secher H Pilegaard, Acta Physiol (Oxf) 2010
22. Variability among the sites by which curaremimetic toxins bind to torpedo acetylcholine receptor, as revealed by identification of the functional residues of alpha-cobratoxin. S Antil D Servent A Menez, J Biol Chem 1999 274 34851 34858 10.1074/jbc.274.49.34851 10574958
23. The protein disulfide-isomerase family: unravelling a string of folds. DM Ferrari HD Soling, Biochem J 1999 339 1 10 10.1042/0264-6021:3390001 10085220
24. Novel genes encoding six kinds of three-finger toxins in Ophiophagus hannah (king cobra) and function characterization of two recombinant long-chain neurotoxins. J Li H Zhang J Liu K Xu, Biochem J 2006 398 233 42 10.1042/BJ20060004 16689684
25. Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. B Friguet AF Chaffotte L Djavadi-Ohaniance ME Goldberg, J Immunol Methods 1985 77 305 319 10.1016/0022-1759(85)90044-4 3981007
26. Selecting and screening recombinant antibody libraries. HR Hoogenboom, Nat Biotechnol 2005 23 1105 1116 10.1038/nbt1126 16151404
27. Minimizing a binding domain from protein A. AC Braisted JA Wells, Proc Natl Acad Sci USA 1996 93 5688 5692 10.1073/pnas.93.12.5688 8650153
28. Directed evolution of high-affinity antibody mimics using mRNA display. L Xu P Aha K Gu RG Kuimelis M Kurz T Lam AC Lim H Liu PA Lohse L Sun S Weng RW Wagner D Lipovsek, Chem Biol 2002 9 933 942 10.1016/S1074-5521(02)00187-4 12204693
29. Directed evolution of ATP binding proteins from a zinc finger domain by using mRNA display. GS Cho JW Szostak, Chem Biol 2006 13 139 147 10.1016/j.chembiol.2005.10.015 16492562
30. Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. G Beste FS Schmidt T Stibora A Skerra, Proc Natl Acad Sci USA 1999 96 1898 1903 10.1073/pnas.96.5.1898 10051566
31. Designing repeat proteins: Well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. HK Binz MT Stumpp P Forrer P Amstutz A Plückthun, J Mol Biol 2003 332 489 503 10.1016/S0022-2836(03)00896-9 12948497
32. Direct demonstration of MuSK involvement in acetylcholine receptor clustering through identification of agonist scFv. MH Xie J Yuan C Adams A Gurney, Nat Biotechnol 1997 15 768 771 10.1038/nbt0897-768 9255792
33. Phage display for epitope determination: a paradigm for identifying receptor-ligand interactions. MJ Rowley K O'Connor L Wijeyewickrema, Biotechnol Annu Rev 2004 10 151 188 15504706
34. A rationally designed agonist antibody fragment that functionally mimics thrombopoietin. S Frederickson MW Renshaw B Lin LM Smith P Calveley JP Springhorn K Johnson Y Wang X Su Y Shen KS Bowdish, Proc Natl Acad Sci USA 2006 103 14307 14312 10.1073/pnas.0602658103 16973749
35. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. SE Cwirla P Balasubramanian DJ Duffin CR Wagstrom CM Gates SC Singer AM Davis RL Tansik LC Mattheakis CM Boytos PJ Schatz DP Baccanari NC Wrighton RW Barrett WJ Dower, Science 1997 276 1696 1699 10.1126/science.276.5319.1696 9180079
36. Isolation of erythropoietin receptor agonist peptides using evolved phage libraries. SJ McConnell T Dinh MH Le SJ Brown K Becherer K Blumeyer C Kautzer F Axelrod DG Spinella, Biol Chem 1998 379 1279 1286 10.1515/bchm.1998.379.10.1279 9820589
37. Recombinant protein folding and misfolding in Escherichia coli. F Baneyx M Mujacic, Nat Biotechnol 2004 22 1399 1408 10.1038/nbt1029 15529165
38. Recombinant expression of alpha-bungarotoxin in Pichia pastoris facilitates identification of mutant toxins engineered to recognize neuronal nicotinic acetylcholine receptors. MM Levandoski PM Caffery RS Rogowski Y Lin QL Shi E Hawrot, J Neurochem 2000 74 1279 1289 10.1046/j.1471-4159.2000.741279.x 10693962
39. The crystal structure of alpha-bungarotoxin at 2.5 resolution: relation to solution structure and binding to acetylcholine receptor. RA Love RM Stroud, Protein Eng 1986 1 37 46 10.1093/protein/1.1.37 3507686
40. The crystal structure of a post-synaptic neurotoxin from sea snake at 2.2 resolution. D Tsernoglou GA Petsko, FEBS Lett 1976 68 1 4 10.1016/0014-5793(76) 80390-0 964372
41. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. J Silverman Q Liu A Bakker W To A Duguay BM Alba R Smith A Rivas P Li H Le E Whitehorn KW Moore C Swimmer V Perlroth M Vogt J Kolkman WP Stemmer, Nat Biotechnol 2005 23 1556 1561 10.1038/nbt1166 16299519
42. Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting. XQ Qiu H Wang B Cai LL Wang ST Yue, Nat Biotechnol 2007 25 921 929 10.1038/nbt1320 17676038
43. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. R Atreya J Mudter S Finotto J Müllberg T Jostock S Wirtz M Schütz B Bartsch M Holtmann C Becker D Strand J Czaja JF Schlaak HA Lehr F Autschbach G Schürmann N Nishimoto K Yoshizaki H Ito T Kishimoto PR Galle S Rose-John MF Neurath, Nat Med 2000 6 583 588 10.1038/75068 10802717
44. Interleukin-6-deficient mice develop mature-onset obesity. V Wallenius K Wallenius B Ahrén M Rudling H Carlsten SL Dickson C Ohlsson JO Jansson, Nat Med 2002 8 75 79 10.1038/nm0102-75 11786910
45. Combined interleukin-6 and interleukin-1 deficiency causes obesity in young mice. D Chida T Osaka O Hashimoto Y Iwakura, Diabetes 2006 55 971 977 10.2337/diabetes.55.04.06.db05-1250 16567518
46. Interleukin 6 promotes vasculogenesis of murine brain microvessel endothelial cells. D Fee D Grzybicki M Dobbs S Ihyer J Clotfelter S Macvilay MN Hart M Sandor Z Fabry, Cytokine 2000 12 655 665 10.1006/cyto.1999.0599 10843741
47. Early IL-6 plasma concentrations correlate with severity of brain injury and pneumonia in brain-injured patients. C Woiciechowsky B Schöning J Cobanov WR Lanksch HD Volk WD Döcke, J Trauma 2002 52 339 45 10.1097/00005373-200202000-00021 11834998
48. Effect of astrocyte-targeted production of IL-6 on traumatic brain injury and its impact on the cortical transcriptome. A Quintana A Molinero R Borup FC Nielsen IL Campbell M Penkowa J Hidalgo, Dev Neurobiol 2008 68 195 208 10.1002/dneu.20584 18000830
49. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. N Nishimoto T Kishimoto K Yoshizaki, Ann Rheum Dis 2000 59 21 27 10.1136/ard.59.suppl-1.i21
50. A novel peptide specifically binding to interleukin-6 receptor (gp80) inhibits angiogenesis and tumor growth. JL Su KP Lai CA Chen CY Yang PS Chen CC Chang CH Chou CL Hu ML Kuo CY Hsieh LH Wei, Cancer Res 2005 65 4827 4835 10.1158/0008-5472.CAN-05-0188 15930303
51. The design of antagonist peptide of hIL-6 based on the binding epitope of hIL-6 by computer-aided molecular modeling. J Feng Y Li B Shen, Peptides 2004 25 1123 1131 10.1016/j.peptides.2004.04.009 15245871
52. The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6. F Martin C Toniatti AL Salvati S Venturini G Ciliberto R Cortese M Sollazzo, EMBO J 1994 13 5303 5309 7957096
53. A designed ankyrin repeat protein evolved to picomolar affinity to Her2. C Zahnd E Wyler JM Schwenk D Steiner MC Lawrence NM McKern F Pecorari CW Ward TO Joos A Plückthun, J Mol Biol 2007 369 1015 1028 10.1016/j.jmb.2007.03.028 17466328
54. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. ET Boder KS Midelfort KD Wittrup, Proc Natl Acad Sci USA 2000 97 10701 10705 10.1073/pnas.170297297 10984501
55. Increased potency of an erythropoietin peptide mimetic through covalent dimerization. NC Wrighton P Balasubramanian FP Barbone AK Kashyap FX Farrell LK Jolliffe RW Barrett WJ Dower, Nat Biotechnol 1997 15 1261 1265 10.1038/nbt1197-1261 9359108
56. Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity. DL Johnson FX Farrell FP Barbone FJ McMahon J Tullai D Kroon J Freedy RA Zivin LS Mulcahy LK Jolliffe, Chem Biol 1997 4 939 950 10.1016/S1074-5521(97)90302-1 9427659
57. PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting. S Kubetzko E Balic R Waibel U Zangemeister-Wittke A Pluckthun, J Biol Chem 2006 281 35186 35201 10.1074/jbc.M604127200 16963450
58. Bock G.H. Long C.A. Riley M.L. White J.D. Kurman C.C. Fleisher T.A. Tsokos M. Brown M. Serbousek D. Schwietermann W.D. Nelson D.L., Characterization of a new IL-6 dependent human B-lymphoma cell line in long term culture, Cytokine, 1993, 5, 480-489, 10.1016/1043-4666(93)90039-8. 8142604.